TRPC6-IN-3 (compound 17) is a potent, orally active transient receptor potential C6 ion channel (TRPC6) inhibitor. TRPC6-IN-3 modulates not only intracellular calcium concentration, but also membrane potential by modulating the flux of cations including calcium and sodium ions. TRPC6-IN-3 can be used in research of respiratory system. In Vivo TRPC6-IN-3 (compound 17; 1-10 mg/kg; p.o.; orally 12 h and 2 h before LPS challenge; LPS-induced mice) inhibits LPS-induced vascular leakage and inhibits accumulation of Broncho-Alveolar-Lavage protein (BALF protein) in a mouse model . TRPC6-IN-3 (3 mg/kg; p.o.; daily, for 4 d; H1N1-induced mice) reduces H1N1-induced vascular leakage in a mouse model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: LPS-induced mice Dosage: 1, 3, and 10 mg/kg Administration: Oral administration; orally 12 h and 2 h before LPS challenge Result: Reduced BALF protein concentration of 56 % at 3 mg/kg and 62 % at 10 mg/kg. Animal Model: H1N1-induced mice Dosage: 3 mg/kg Administration: Oral administration; daily, for 4 days Result: Inhibited Evans blue extravasation from the blood to the BALF and reduced BALF Evans blue by 24 % at 3 mg/kg. Form:Solid